Microvillus inclusion disease: From organoids to new treatments
These cells had been pretty screwed up before ... for the development of therapeutic approaches in microvillus inclusion ...
BioSpace2d
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
Sickle cell disease is a genetic disorder that causes lifelong suffering – here’s what you need to know
Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...
Health Affairs10d
Filling The Gaps: The Urgent Need For Sickle Cell Disease Data
Our fundamental challenge is not simply to create the data. Rather, it is to collect and analyze it systematically. Doing so ...
Medical Xpress on MSN21d
Dysregulated inclusion of BOLA3 exon 3 promoted by HNRNPC accelerates the progression of esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis, and understanding the ...
FierceBiotech2d
Sanofi-backed Abcuro raises $200M series C to fund pivotal trial of KLRG1 antibody
Sanofi-backed Abcuro has secured $200 million in series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle ...
GlobalData on MSN2d
Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
PipelineReview.com2d
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...